nach oben

Journal of Gastrointestinal Cancer

Erschienen in:

23.07.2020 | Review Article

CAR T Cell Therapy in Pancreaticobiliary Cancers: a Focused Review of Clinical Data

verfasst von: Muhammad Yasir Anwar, Grant R. Williams, Ravi K. Paluri

Erschienen in: Journal of Gastrointestinal Cancer | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Objective

CAR T cell therapy is an innovative approach to treat cancers in the modern era. It utilizes the application of chimeric antigen receptors targeted against specific antigens expressed by the tumor cells. Although its efficacy is established in hematological malignancies, the safety and efficacy of this therapy in solid tumors, especially pancreaticobiliary cancers, is a highly investigated aspect. A focused review of clinical data was conducted to examine the outcomes of this therapy in pancreaticobiliary cancers.

Methods

A comprehensive literature search was done on Medline and Embase databases through April 24, 2020 for studies that evaluated the outcomes of CAR T cell therapy in pancreaticobiliary cancers.

Results

There were six phase 1 trials, while one was phase 1/2. Some of these trials were specifically done for pancreaticobiliary cancers, while others included patients of various solid organ cancers, including pancreatic and biliary tract cancers. The target antigens for therapy in these trials included mesothelin, CD133, prostate stem cell antigen, claudin 18.2, epidermal growth factor receptor, and human epidermal growth factor receptor 2. CAR T cell therapy has shown very few grade 3 and 4 side effects. Most of the adverse events are associated with cytokine release syndrome.

Conclusion

CAR T cell therapy has a manageable safety profile based on phase 1 studies, and efficacy assessments are currently ongoing in dose expansion and phase 2 studies.

Sadelain M, Brentjens R, Rivière I. The promise and potential pitfalls of chimeric antigen receptors. Curr Opin Immunol. 2009;21(2):215–23. https://doi.org/10.1016/j.coi.2009.02.009.CrossRefPubMedPubMedCentral

Stern LA, Jonsson VD, Priceman SJ. CAR T cell therapy progress and challenges for solid tumors. Cancer Treat Res. 2020;180:297–326. https://doi.org/10.1007/978-3-030-38862-1_11.CrossRefPubMed

Billingham RE, Brent L, Medawar PB, Sparrow EM. Quantitative studies on tissue transplantation immunity. I. The survival times of skin homografts exchanged between members of different inbred strains of mice. Proc R Soc Lond B Biol Sci. 1954;143(910):43–58. https://doi.org/10.1098/rspb.1954.0053.CrossRefPubMed

Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365(8):725–33. https://doi.org/10.1056/NEJMoa1103849.CrossRefPubMedPubMedCentral

Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, Feldman SA, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood. 2010;116(20):4099–102. https://doi.org/10.1182/blood-2010-04-281931.CrossRefPubMedPubMedCentral

van der Stegen SJC, Hamieh M, Sadelain M. The pharmacology of second-generation chimeric antigen receptors. Nat Rev Drug Discov. 2015;14(7):499–509. https://doi.org/10.1038/nrd4597.CrossRefPubMedPubMedCentral

Allegra A, Innao V, Gerace D, Vaddinelli D, Musolino C. Adoptive immunotherapy for hematological malignancies: current status and new insights in chimeric antigen receptor T cells. Blood Cells Mol Dis. 2016;62:49–63. https://doi.org/10.1016/j.bcmd.2016.11.001.CrossRefPubMed

Kueberuwa G, Kalaitsidou M, Cheadle E, Hawkins RE, Gilham DE. CD19 CAR T cells expressing IL-12 eradicate lymphoma in fully lymphoreplete mice through induction of host immunity. Mol Ther Oncolytics. 2018;8:41–51. https://doi.org/10.1016/j.omto.2017.12.003.CrossRefPubMed

Park JH, Rivière I, Gonen M, Wang X, Sénéchal B, Curran KJ, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378(5):449–59. https://doi.org/10.1056/NEJMoa1709919.CrossRefPubMedPubMedCentral

10.

Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507–17. https://doi.org/10.1056/NEJMoa1407222.CrossRefPubMedPubMedCentral

11.

Brown CE, Alizadeh D, Starr R, Weng L, Wagner JR, Naranjo A, et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N Engl J Med. 2016;375(26):2561–9. https://doi.org/10.1056/NEJMoa1610497.CrossRefPubMedPubMedCentral

12.

Heczey A, Louis CU, Savoldo B, Dakhova O, Durett A, Grilley B, et al. CAR T cells administered in combination with lymphodepletion and PD-1 inhibition to patients with neuroblastoma. Mol Ther. 2017;25(9):2214–24. https://doi.org/10.1016/j.ymthe.2017.05.012.CrossRefPubMedPubMedCentral

13.

Köksal H, Müller E, Inderberg EM, Bruland Ø, Wälchli S. Treating osteosarcoma with CAR T cells. Scand J Immunol. 2019;89(3):e12741. https://doi.org/10.1111/sji.12741.CrossRefPubMed

14.

Bagley SJ, O’Rourke DM. Clinical investigation of CAR T cells for solid tumors: lessons learned and future directions. Pharmacol Ther. 2020;205(no pagination):107419. https://doi.org/10.1016/j.pharmthera.2019.107419.

15.

Abakushina EV, Gelm YV, Pasova IA, Bazhin AV. Immunotherapeutic approaches for the treatment of colorectal cancer. Biochemistry (Mosc). 2019;84(7):720–8. https://doi.org/10.1134/s0006297919070046.CrossRef

16.

Zhu CZ, Liu D, Kang WM. Immunotherapy of gastrointestinal stromal tumors. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2019;41(5):696–701. https://doi.org/10.3881/j.issn.1000-503X.11097.CrossRefPubMed

17.

Nishida T, Kataoka H. Glypican 3-targeted therapy in hepatocellular carcinoma. Cancers (Basel). 2019;11(9). https://doi.org/10.3390/cancers11091339.

18.

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30. https://doi.org/10.3322/caac.21387.CrossRefPubMed

19.

Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med. 2014;371(11):1039–49. https://doi.org/10.1056/NEJMra1404198.CrossRefPubMed

20.

Varghese AM. Chimeric antigen receptor (CAR) T and other T cell strategies for pancreas adenocarcinoma. Chin Clin Oncol. 2017;6(6):66. https://doi.org/10.21037/cco.2017.09.04.CrossRefPubMed

21.

Feng K, Liu Y, Guo Y, Qiu J, Wu Z, Dai H, et al. Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers. Protein Cell. 2018;9(10):838–47. https://doi.org/10.1007/s13238-017-0440-4.CrossRefPubMed

22.

Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen MC, Plesa G, et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res. 2014;2(2):112–20. https://doi.org/10.1158/2326-6066.Cir-13-0170.CrossRefPubMed

23.

Becerra CR, Manji GA, Kim DW, Gardner O, Malankar A, Shaw J, et al. Ligand-inducible, prostate stem cell antigen (PSCA)-directed GoCAR-T cells in advanced solid tumors: preliminary results with cyclophosphamide (Cy) +/- fludarabine (Flu) lymphodepletion (LD). J Clin Oncol Conference. 2019;37(Supplement 15). https://doi.org/10.1200/JCO.2019.37.15-suppl.2536.

24.

Yazdanifar M, Zhou R, Grover P, Williams C, Bose M, Moore LJ, et al. Overcoming immunological resistance enhances the efficacy of a novel anti-tMUC1-CAR T cell treatment against pancreatic ductal adenocarcinoma. Cells. 2019;8(9). https://doi.org/10.3390/cells8091070.

25.

Zhan X, Wang B, Li Z, Li J, Wang H, Chen L, et al. Phase I trial of Claudin 18.2-specific chimeric antigen receptor T cells for advanced gastric and pancreatic adenocarcinoma. J Clin Oncol Conference. 2019;37(Supplement 15). https://doi.org/10.1200/JCO.2019.37.15_suppl.2509.

26.

Kruger S, Ilmer M, Kobold S, Cadilha BL, Endres S, Ormanns S, et al. Advances in cancer immunotherapy 2019 - latest trends. J Exp Clin Cancer Res. 2019;38(1):268. https://doi.org/10.1186/s13046-019-1266-0.CrossRefPubMedPubMedCentral

27.

Hou B, Tang Y, Li W, Zeng Q, Chang D. Efficiency of CAR-T therapy for treatment of solid tumor in clinical trials: a meta-analysis. Dis Markers. 2019;2019:3425291–11. https://doi.org/10.1155/2019/3425291.CrossRefPubMedPubMedCentral

28.

Chang K, Pastan I, Willingham MC. Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. Int J Cancer. 1992;50(3):373–81. https://doi.org/10.1002/ijc.2910500308.CrossRefPubMed

29.

O’Hara M, Stashwick C, Haas AR, Tanyi JL. Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy. Immunotherapy. 2016;8(4):449–60. https://doi.org/10.2217/imt.16.4.CrossRefPubMedPubMedCentral

30.

Argani P, Iacobuzio-Donahue C, Ryu B, Rosty C, Goggins M, Wilentz RE, et al. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res. 2001;7(12):3862–8.PubMed

31.

Hassan R, Laszik ZG, Lerner M, Raffeld M, Postier R, Brackett D. Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis. Am J Clin Pathol. 2005;124(6):838–45.CrossRef

32.

Einama T, Kawamata F, Kamachi H, Nishihara H, Homma S, Matsuzawa F, et al. Clinical impacts of mesothelin expression in gastrointestinal carcinomas. World J Gastrointest Pathophysiol. 2016;7(2):218–22. https://doi.org/10.4291/wjgp.v7.i2.218.CrossRefPubMedPubMedCentral

33.

Beatty GL, O’Hara MH, Lacey SF, Torigian DA, Nazimuddin F, Chen F, et al. Activity of mesothelin-specific chimeric antigen receptor T cells against pancreatic carcinoma metastases in a phase 1 trial. Gastroenterology. 2018;155(1):29–32. https://doi.org/10.1053/j.gastro.2018.03.029.CrossRefPubMedPubMedCentral

34.

Haas AR, Tanyi JL, O’Hara MH, Gladney WL, Lacey SF, Torigian DA, et al. Phase I study of lentiviral-transduced chimeric antigen receptor-modified T cells recognizing mesothelin in advanced solid cancers. Mol Ther. 2019;27(11):1919–29. https://doi.org/10.1016/j.ymthe.2019.07.015.CrossRefPubMedPubMedCentral

35.

Ren F, Sheng WQ, Du X. CD133: a cancer stem cells marker, is used in colorectal cancers. World J Gastroenterol. 2013;19(17):2603–11. https://doi.org/10.3748/wjg.v19.i17.2603.CrossRefPubMedPubMedCentral

36.

Glumac PM, LeBeau AM. The role of CD133 in cancer: a concise review. Clin Transl Med. 2018;7(1):18. https://doi.org/10.1186/s40169-018-0198-1.CrossRefPubMedPubMedCentral

37.

Park YY, An CH, Oh ST, Chang ED, Lee J. Expression of CD133 is associated with poor prognosis in stage II colorectal carcinoma. Medicine (Baltimore). 2019;98(32):e16709. https://doi.org/10.1097/md.0000000000016709.CrossRef

38.

Yu GF, Lin X, Luo RC, Fang WY. Nuclear CD133 expression predicts poor prognosis for hepatocellular carcinoma. Int J Clin Exp Pathol. 2018;11(4):2092–9.PubMedPubMedCentral

39.

Feng KC, Guo YL, Liu Y, Dai HR, Wang Y, Lv HY, et al. Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma. J Hematol Oncol. 2017;10(1):4. https://doi.org/10.1186/s13045-016-0378-7.CrossRefPubMedPubMedCentral

40.

Wang Y, Chen M, Wu Z, Tong C, Dai H, Guo Y, et al. CD133-directed CAR T cells for advanced metastasis malignancies: a phase I trial. OncoImmunology. 2018;7(7). https://doi.org/10.1080/2162402X.2018.1440169.

41.

Furuse M, Fujita K, Hiiragi T, Fujimoto K, Tsukita S. Claudin-1 and -2: novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin. J Cell Biol. 1998;141(7):1539–50. https://doi.org/10.1083/jcb.141.7.1539.CrossRefPubMedPubMedCentral

42.

Resnick MB, Konkin T, Routhier J, Sabo E, Pricolo VE. Claudin-1 is a strong prognostic indicator in stage II colonic cancer: a tissue microarray study. Mod Pathol. 2005;18(4):511–8. https://doi.org/10.1038/modpathol.3800301.CrossRefPubMed

43.

Sanada Y, Oue N, Mitani Y, Yoshida K, Nakayama H, Yasui W. Down-regulation of the claudin-18 gene, identified through serial analysis of gene expression data analysis, in gastric cancer with an intestinal phenotype. J Pathol. 2006;208(5):633–42. https://doi.org/10.1002/path.1922.CrossRefPubMed

44.

Cheung ST, Leung KL, Ip YC, Chen X, Fong DY, Ng IO, et al. Claudin-10 expression level is associated with recurrence of primary hepatocellular carcinoma. Clin Cancer Res. 2005;11(2 Pt 1):551–6.PubMed

45.

Morin PJ. Claudin proteins in human cancer: promising new targets for diagnosis and therapy. Cancer Res. 2005;65(21):9603–6. https://doi.org/10.1158/0008-5472.Can-05-2782.CrossRefPubMed

46.

Saeki N, Gu J, Yoshida T, Wu X. Prostate stem cell antigen: a Jekyll and Hyde molecule? Clin Cancer Res. 2010;16(14):3533–8. https://doi.org/10.1158/1078-0432.Ccr-09-3169.CrossRefPubMedPubMedCentral

47.

Sharom FJ, Radeva G. GPI-anchored protein cleavage in the regulation of transmembrane signals. Subcell Biochem. 2004;37:285–315. https://doi.org/10.1007/978-1-4757-5806-1_9.CrossRefPubMed

48.

Reiter RE, Gu Z, Watabe T, Thomas G, Szigeti K, Davis E, et al. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci U S A. 1998;95(4):1735–40. https://doi.org/10.1073/pnas.95.4.1735.CrossRefPubMedPubMedCentral

49.

Sun X, Liu S, Wang D, Zhang Y, Li W, Guo Y, et al. Colorectal cancer cells suppress CD4+ T cells immunity through canonical Wnt signaling. Oncotarget. 2017;8(9):15168–81. https://doi.org/10.18632/oncotarget.14834.CrossRefPubMedPubMedCentral

50.

Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2(2):127–37. https://doi.org/10.1038/35052073.CrossRefPubMed

51.

Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 2000;19(13):3159–67. https://doi.org/10.1093/emboj/19.13.3159.CrossRefPubMedPubMedCentral

52.

Normanno N, Bianco C, De Luca A, Salomon DS. The role of EGF-related peptides in tumor growth. Front Biosci. 2001;6:D685–707. https://doi.org/10.2741/normano.CrossRefPubMed

53.

Yamaoka T, Ohba M, Ohmori T. Molecular-targeted therapies for epidermal growth factor receptor and its resistance mechanisms. Int J Mol Sci. 2017;18(11). https://doi.org/10.3390/ijms18112420.

54.

Guo Y, Feng K, Liu Y, Wu Z, Dai H, Yang Q, et al. Phase I study of chimeric antigen receptor-modified T cells in patients with EGFR-positive advanced biliary tract cancers. Clin Cancer Res. 2018;24(6):1277–86. https://doi.org/10.1158/1078-0432.CCR-17-0432.CrossRefPubMed

55.

Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW Jr, et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature. 2003;421(6924):756–60. https://doi.org/10.1038/nature01392.CrossRefPubMed

56.

Riese DJ 2nd, Stern DF. Specificity within the EGF family/ErbB receptor family signaling network. Bioessays. 1998;20(1):41–8. https://doi.org/10.1002/(sici)1521-1878(199801)20:1<41::Aid-bies7>3.0.Co;2-v.CrossRefPubMed

57.

Burstein HJ. The distinctive nature of HER2-positive breast cancers. N Engl J Med. 2005;353(16):1652–4. https://doi.org/10.1056/NEJMp058197.CrossRefPubMed

58.

Berchuck A, Kamel A, Whitaker R, Kerns B, Olt G, Kinney R, et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res. 1990;50(13):4087–91.PubMed

59.

Santin AD, Bellone S, Van Stedum S, Bushen W, Palmieri M, Siegel ER, et al. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma. Cancer. 2005;104(7):1391–7. https://doi.org/10.1002/cncr.21308.CrossRefPubMed

60.

Tanner M, Hollmén M, Junttila TT, Kapanen AI, Tommola S, Soini Y, et al. Amplification of HER-2 in gastric carcinoma: association with topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol. 2005;16(2):273–8. https://doi.org/10.1093/annonc/mdi064.CrossRefPubMed

61.

Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673–84. https://doi.org/10.1056/NEJMoa052122.CrossRefPubMed

62.

Zhou R, Yazdanifar M, Roy LD, Whilding LM, Gavrill A, Maher J, et al. CAR T cells targeting the tumor MUC1 glycoprotein reduce triple-negative breast cancer growth. Front Immunol. 2019;10:1149. https://doi.org/10.3389/fimmu.2019.01149.CrossRefPubMedPubMedCentral

63.

PersonGen BioTherapeutics Co. L, Hefei TFPsHo, Hospital HB. CAR-pNK cell immunotherapy in MUC1 positive relapsed or refractory solid tumor. 2016. https://ClinicalTrials.gov/show/NCT02839954,

64.

PersonGen BioTherapeutics Co. L, Hefei TFPsHo, Hospital HB. Phase I/II study of anti-Mucin1 (MUC1) CAR T cells for patients with MUC1+ advanced refractory solid tumor. 2015. https://ClinicalTrials.gov/show/NCT02587689,

65.

DeSelm CJ, Tano ZE, Varghese AM, Adusumilli PS. CAR T-cell therapy for pancreatic cancer. J Surg Oncol. 2017;116(1):63–74. https://doi.org/10.1002/jso.24627.CrossRefPubMed

66.

Wang Z, Han W. Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy. Biomark Res. 2018;6:4. https://doi.org/10.1186/s40364-018-0116-0.CrossRefPubMedPubMedCentral

67.

Frey NV, Porter DL. Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2016;2016(1):567–72. https://doi.org/10.1182/asheducation-2016.1.567.CrossRefPubMedPubMedCentral

68.

Martinez M, Moon EK. CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment. Front Immunol. 2019;10:128. https://doi.org/10.3389/fimmu.2019.00128.CrossRefPubMedPubMedCentral

69.

Labanieh L, Majzner RG, Mackall CL. Programming CAR-T cells to kill cancer. Nat Biomed Eng. 2018;2(6):377–91. https://doi.org/10.1038/s41551-018-0235-9.CrossRefPubMed

70.

Gajewski TF, Meng Y, Blank C, Brown I, Kacha A, Kline J, et al. Immune resistance orchestrated by the tumor microenvironment. Immunol Rev. 2006;213:131–45. https://doi.org/10.1111/j.1600-065X.2006.00442.x.CrossRefPubMed

71.

Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A. 2002;99(19):12293–7. https://doi.org/10.1073/pnas.192461099.CrossRefPubMedPubMedCentral

72.

Gorelik L, Flavell RA. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat Med. 2001;7(10):1118–22. https://doi.org/10.1038/nm1001-1118.CrossRefPubMed

73.

Pegram HJ, Lee JC, Hayman EG, Imperato GH, Tedder TF, Sadelain M, et al. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood. 2012;119(18):4133–41. https://doi.org/10.1182/blood-2011-12-400044.CrossRefPubMedPubMedCentral

74.

John LB, Devaud C, Duong CP, Yong CS, Beavis PA, Haynes NM, et al. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res. 2013;19(20):5636–46. https://doi.org/10.1158/1078-0432.Ccr-13-0458.CrossRefPubMed

75.

Katz SC, Burga RA, McCormack E, Wang LJ, Mooring W, Point GR, et al. Phase I hepatic immunotherapy for metastases study of intra-arterial chimeric antigen receptor-modified T-cell therapy for CEA+ liver metastases. Clin Cancer Res. 2015;21(14):3149–59. https://doi.org/10.1158/1078-0432.Ccr-14-1421.CrossRefPubMedPubMedCentral

76.

Moon EK, Carpenito C, Sun J, Wang LC, Kapoor V, Predina J, et al. Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. Clin Cancer Res. 2011;17(14):4719–30. https://doi.org/10.1158/1078-0432.Ccr-11-0351.CrossRefPubMedPubMedCentral

77.

Caruana I, Savoldo B, Hoyos V, Weber G, Liu H, Kim ES, et al. Heparanase promotes tumor infiltration and anti-tumor activity of CAR-redirected T lymphocytes. Nat Med. 2015;21(5):524–9. https://doi.org/10.1038/nm.3833.CrossRefPubMedPubMedCentral

Titel: CAR T Cell Therapy in Pancreaticobiliary Cancers: a Focused Review of Clinical Data
verfasst von: Muhammad Yasir Anwar
Grant R. Williams
Ravi K. Paluri
Publikationsdatum: 23.07.2020
Verlag: Springer US
Erschienen in: Journal of Gastrointestinal Cancer / Ausgabe 1/2021
Print ISSN: 1941-6628
Elektronische ISSN: 1941-6636
DOI: https://doi.org/10.1007/s12029-020-00457-1

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

CAR T Cell Therapy in Pancreaticobiliary Cancers: a Focused Review of Clinical Data

Abstract

Objective

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Update Onkologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Objective

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2021

Evaluation of Ferritin and Transferrin Ratio as a Prognostic Marker for Hepatocellular Carcinoma

Is it Possible to Increase Survival of Patients with Intrahepatic Cholangiocarcinoma? A Case Report

Esophageal Cancer and Double Aortic Arch: Right-Sided Thoracoscopic Esophagectomy and Reconstruction

Factors to Improve Endoscopic Screening for Colorectal Cancer

An Evaluation of the Fecal Microbiome in Lynch Syndrome

The Effect of Inflammatory Markers on Survival in Advanced Biliary Tract Carcinoma Treated with Gemcitabine/Oxaliplatin Regimen

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Update Onkologie